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ABSTRACT 
The MDM2 RING domain harbors E3 
ubiquitin ligase activity critical for regulating 
the degradation of tumor suppressor p53, 
which controls many cellular pathways. The 
MDM2 RING domain also is required for an 
interaction with MDMX. Mice containing a 
substitution in the MDM2 RING domain, 
MDM2C462A, disrupting MDM2 E3 function and 
the MDMX interaction, die during early 
embryogenesis that can be rescued by p53 
deletion. To investigate whether MDM2C462A, 
which retains p53 binding, has p53-suppressing 
activity, we generated Mdm2C462A/C462A;p53ER/- 
mice, in which we replaced the endogenous p53 
alleles with an inducible p53ER/- allele, and 
compared survival with that of similarly 
generated Mdm2-/-;p53ER/- mice. Adult Mdm2-
null mice died ~7 days after tamoxifen-induced 
p53 activation, indicating that in the absence of 
MDM2, MDMX cannot suppress p53. 
Surprisingly, Mdm2C462A/C462A;p53ER/- mice died 
~5 days after tamoxifen injection, suggesting 
that p53 activity is higher in the presence of 
MDM2C462A than in the absence of MDM2. 
Indeed, in MDM2C462A-expressing mouse tissues 
and embryonic fibroblasts, p53 exhibited 
higher transcriptional activity than in those 
expressing no MDM2 or no MDM2 and 
MDMX. This observation indicated that 
MDM2C462A not only is unable to suppress p53 
but may have gained the ability to enhance p53 
activity. We also found that p53 acetylation, a 
measure of p53 transcriptional activity, was 
higher in the presence of MDM2C462A than in 
the absence of MDM2. These results reveal an 
unexpected role of MDM2C462A in enhancing 
p53 activity and suggest the possibility that 
compounds targeting MDM2 RING domain 




As a transcription factor, p53 induces the 
transcription of several downstream targets in the 
presence of both intrinsic and extrinsic cellular 
stress signals; many of these targets regulate the 
cell cycle, apoptosis, DNA repair, senescence, and 
angiogenesis, and other cellular pathways (1-4). 
The activation of p53-dependent pathways is 
thought to prevent and resist tumor development 
and growth by preventing the proliferation of 
damaged cells with oncogenic potential. For that 
reason, p53 has been called “the guardian of 
genome” due to its indispensable contribution to 
genome integrity (5-7). However, because of its 
global and heterogeneous functions, endogenous 
p53 activity must also be carefully regulated. 
Murine double minute 2 (MDM2) and 4 
(MDM4, also known as MDMX) are widely 
considered to be the primary negative regulators of 
p53 (8, 9). Considering that Mdm2 and MdmX 
knockout mice exhibit p53-dependent early 
embryonic lethality, MDM2 and MDMX play 
unique and nonredundant roles in the control of 
p53 activation (10-12). Though MDM2 and 
MDMX are structurally similar, they exhibit 
differing activities towards p53 regulation. 
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Through its RING domain, MDM2 not only 
functions as an E3 ubiquitin ligase for p53 (13-15) 
but also binds to MDMX in a heterodimer that is 
required for p53 regulation during embryogenesis 
(16, 17). Recent evidence has demonstrated that 
the RING finger motif of MDM2 is indispensable 
for the suppression of p53 activity (18, 19), and 
we have previously demonstrated that the MDM2 
RING domain plays a crucial role in p53 
regulation during embryonic development (14). 
Interestingly, two functions of the MDM2 RING 
domain, E3 ubiquitin ligase activity and MDMX 
binding, have been found to be independently 
dispensable in unstressed adult mice (15, 17). 
Thus, the function of RING domain towards the 
regulation of physiological p53 transcriptional 
activity in the adult mouse still remains 
inadequately understood. In this study we sought 
to address the following questions: (1) Does the 
MDM2 RING domain function to regulate p53 
transcriptional activity in adult mice? (2) Is 
MDM2-p53 binding sufficient for p53 regulation 
and adult organismal survival? (3) In the absence 
of MDM2 or MDM2 RING domain function, does 
MDMX play a role in regulating p53 
transcriptional activity in adult mice? 
To study the role of the MDM2 RING 
domain in vivo, we crossed mice bearing a single 
residue substitution in the MDM2 RING domain 
(Mdm2C462A/C462A) that abolishes several key RING 
domain functions, including MDM2 E3 ligase 
activity and MDM2-MDMX binding. Since 
Mdm2C462A/C462A single-residue substitution results 
in the embryonic lethality, we substituted 
endogenous p53 with p53ER/-, an inactive p53 
estrogen receptor fusion allele, which allows for 
tamoxifen mediated p53 functional restoration 
(20).  At the same time, we generated 
Mdm2+/+;p53ER/- and Mdm2-/-;p53ER/- as control 
groups in order to define the function of the 
MDM2 RING domain on regulation of 
physiological p53. Strikingly, following p53ER 
functional restoration, mice bearing the 
MDM2C462A mutation die earlier than mice bearing 
MDM2 deletion, and this early lethality correlates 
with increased p53 activity. These results provide 
evidence to suggest that loss of MDM2 RING 
domain function through MDM2C462A mutation 
stimulates spontaneous p53 activation beyond 
what occurs when MDM2 is deleted.  
 
RESULTS 
Mice expressing a functionally inactive Mdm2 
RING domain exhibit early lethality following p53 
activation—In vitro, MDM2 has been shown to 
modulate p53 transcriptional activity by direct 
inhibitory binding to the p53 transactivation 
domain (21, 22). The RING domain of MDM2, 
which is important for MDM2-mediated p53 
ubiquitination and degradation and MDM2-
MDMX heterodimer formation, is also critical for 
p53 regulation in vivo. Several studies using 
mouse models have suggested that each of these 
RING domain functions are important to p53 
regulation during embryogenesis; however, 
MDM2-MDMX binding and MDM2 E3 ligase 
activity have been shown to be independently 
dispensable in the adult mouse (14, 15, 17). To 
confirm whether MDM2 retains p53 inhibitory 
capabilities in the absence of either of the 
canonical MDM2 RING domain functions in adult 
mice, we utilized mice bearing the MDM2C462A 
mutation (Mdm2C462A/C462A), which disrupts both 
MDM2-MDMX binding and MDM2 E3 ligase 
function. Because Mdm2C462A/C462A mice exhibit 
p53-dependent embryonic lethality (14), we also 
utilized mice bearing the inactive p53 estrogen 
receptor fusion allele (hereafter referred to as 
p53ER) which allows for tamoxifen mediated p53 
functional restoration (20). We crossed 
Mdm2C462A/C462A mice with p53ER/- mice to generate 
Mdm2C462A/C462A;p53ER/- mice. We also generated 
the mice with the following genotypes as positive 
and negative controls for MDM2 function, 
respectively: Mdm2+/+;p53ER/- and Mdm2-/-;p53ER/-. 
Previous studies have shown that Mdm2+/+;p53ER/- 
mice tolerate daily injections of tamoxifen (20). 
Our study replicated these results. Following daily 
injection of tamoxifen, Mdm2+/+;p53ER/- mice 
survived the duration of the study (up to 40 days) 
with no apparent abnormalities. Surprisingly, 
under the same conditions the maximum survival 
time of Mdm2C462A/C462A;p53ER/- mice was 
approximately 4-5 days (Figure 1A). This 
dramatic difference between 
Mdm2C462A/C462A;p53ER/- and Mdm2+/+;p53ER/- mice 
suggests that a functional MDM2 RING domain is 
integral for maintaining homeostasis in adult mice. 
Further, mice lacking MDM2 (Mdm2-/-;p53ER/-) 
have been shown to perish approximately 6 days 
after a single tamoxifen injection (23). We also 
compared the survival of Mdm2C462A/C462A;p53ER/- 
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mice with that of Mdm2-/-;p53ER/- mice following 
tamoxifen injection. Surprisingly, we found that 
Mdm2C462A/C462A;p53ER/- mice lived an evidently 
shorter lifespan than Mdm2-/-;p53ER/- mice (Figure 
1B), which suggests that loss of MDM2 RING 
domain function through the MDM2C462A mutation 
may alter MDM2 functions towards p53 regulation 
and enhance p53 function. Since the MDM2C462A 
mutation disrupts MDM2-MDMX interaction and 
MDMX has been shown to be important for 
MDM2-mediated p53 regulation (24-26), we 
sought to determine whether the differences in 
survival between Mdm2C462A/C462A;p53ER/- mice and 
either Mdm2+/+;p53ER/- mice or Mdm2-/-;p53ER/- 
mice could be dependent on differential MDMX 
protein stability or p53 regulation. To this end, we 
generated each of these mice in the background of 
MdmX deletion. We found that following 
tamoxifen injection, the median survival time of 
Mdm2C462A/C462A;MdmX-/-;p53ER/- mice was 
significantly shorter than that of Mdm2-/-;MdmX-/-; 
p53ER/- mice (Figure 1C) and was equivalent to 
Mdm2C462A/C462A;p53ER/- mice (Figure 1D), 
indicating that changes in MDMX-mediated p53 
regulation or protein stability are unlikely to 
contribute to survival differences present in 
Mdm2C462A/C462A;p53ER/- mice. Further, the loss of 
MDMX did not contribute to changes in survival 
upon Mdm2 deletion, as Mdm2-/-;MdmX-/-;p53ER/- 
mice and Mdm2-/-;p53ER/- mice display similar 
survival times following tamoxifen injection 
(Figure 1E), suggesting that in the absence of 
MDM2, MDMX plays a minimal role in 
contributing to organismal survival during basal 
levels of p53 activity. This notion is in line with 
previous studies in MdmX-/-; p53ER/- mice, which 
tolerate daily injections of tamoxifen for a median 
of ~29 days (27), which showed the significantly 
longer than Mdm2-/-; p53ER/- surviving 7 days. 
 
Loss of Mdm2 RING domain function exacerbates 
intestinal atrophy and cell apoptosis—Because 
loss of MDM2 in p53ER/- mice leads to p53-
induced apoptosis and organismal lethality, we 
sought to determine whether 
Mdm2C462A/C462A;p53ER/- mouse death is correlated 
with changes in tissue homeostasis, including 
increased apoptosis. We injected tamoxifen into 
Mdm2+/+;p53ER/-, Mdm2-/-;p53ER/-, 
Mdm2C462A/C462A;p53ER/-, Mdm2C462A/C462A;MdmX-/-
;p53ER/- and Mdm2-/-;MdmX-/-;p53ER/- mice once 
daily for three days and then collected tissues 
sensitive to p53-induced apoptosis, including 
colon and small intestine. We first performed 
H&E staining in order to observe any changes in 
tissue architecture. The overall integrity of both 
small intestine and colon tissues harvested from 
Mdm2+/+;p53ER/- mice was maintained, and these 
tissues appeared relatively normal (Figure 2A-B). 
In contrast, the small intestine and colon from 
Mdm2C462A/C462A;p53ER/- or Mdm2C462A/C462A;MdmX-/-
;p53ER/- exhibited severe intestinal atrophy 
characterized by shortening of villi and marked 
hypocellularity of crypts compared with the 
corresponding MDM2 WT and MDM2-null 
control groups. In order to detect apoptosis in 
these tissues, we performed a TUNEL assay. 
Colon tissue from Mdm2C462A/C462A;p53ER/- mice 
exhibited more extensive apoptosis compared to 
either Mdm2+/+;p53ER/- or Mdm2-/-;p53ER/- colon 
tissue (Figure 2C). Small intestine from 
Mdm2C462A/C462A;p53ER/- mice exhibited light 
TUNEL staining compared to Mdm2-/-;p53ER/- 
mice (Figure 2D), but we suspect that may be 
because the majority of cells from 
Mdm2C462A/C462A;p53ER/- small intestine have 
already completed the apoptotic process by this 
time, as indicated by a reduction in nuclear 
staining (blue). Notably, Mdm2C462A/C462A;MdmX-/-
;p53ER/- tissues exhibited similar morphological 
changes to Mdm2C462A/C462A;p53ER/- tissues, which 
suggests that MDMX does not play a role in the 
morphological changes. 
 
Mdm2 RING mutation enhances p53 target gene 
transcription—The accelerated organismal 
lethality and increased apoptosis in tissues of 
Mdm2C462A/C462A;p53ER/- mice is consistent with 
increased p53 activity. In order to assess the effect 
of the MDM2C462A mutation on p53 transcriptional 
activity, we isolated mouse embryonic fibroblasts 
(MEFs) from each of the five genotypes and 
treated these cells with 4-hydroxytamoxifen (4-
OHT). We then utilized qRT-PCR to detect 
changes in the transcription of several p53 target 
genes including p21, puma and bax (Figure 3A) 
(28-30). Consistent with previous studies, p21 
transcription was elevated in Mdm2+/+;p53ER/- 
MEFs and was increased to a greater degree in 
Mdm2-/-;p53ER/- MEFs (23). While puma and bax 
transcription were nearly unchanged following 4-
OHT treatment in Mdm2+/+;p53ER/- MEFs, an 
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increase in their transcription was apparent in 
Mdm2-/-;p53ER/- MEFs. Interestingly, following 4-
OHT treatment, p21, bax, and puma transcription 
were significantly increased in 
Mdm2C462A/C462A;p53ER/- MEFs to an even greater 
extent than in Mdm2-/-;p53ER/- or Mdm2-/-;MdmX-/-
;p53ER/- MEFs, suggesting that p53 activity is 
greatest in Mdm2C462A/C462A;p53ER/- MEFs. Further, 
the deletion of MDMX did not significantly alter 
p53 activity in the presence of the MDM2C462A 
mutation. In order to confirm these observations in 
vivo, we harvested small intestine and lung from 
the p53ER mice after the daily administration of 
tamoxifen for 3 days. The trend that we observed 
in MEFs was also reflected in mouse tissue, 
including small intestine and lung, with 
Mdm2C462A/C462A;p53ER/- and 
Mdm2C462A/C462A;MdmX-/-;p53ER/- mice exhibiting 
the highest expression of each target gene (Figure 
3B-C). Intriguingly, since mice bearing the 
MDM2C462A mutation exhibit greater p53 activity 
than mice lacking MDM2 altogether, these data 
suggest the possibility that MDM2-mediated p53 
activity suppression is dependent on MDM2 RING 
function, and in the absence of this function 
MDM2 may have alternate p53 regulating 
capabilities in vivo.  
 
Mdm2 RING functional inactivation potentiates 
p53 acetylation and downstream target gene 
expression—To confirm whether the shortened 
survival time of Mdm2C462A/C462A;p53ER/- mice is 
associated with p53 transcriptional activation at 
the protein level, we cultured early-passage MEFs 
in either the absence or presence of 4-OHT for 
different time points. Then, we assayed the 
expression of p53 target genes p21 and MDM2 
(Figure 4A). In Mdm2+/+;p53ER/- MEFs, MDM2 
and p21 levels were increased after 4-OHT 
exposure, which is consistent with the idea that 
that the activation of p53ER by 4-OHT results in 
increased mdm2 and p21 transcription and 
translation. Consistent with in vivo survival trends, 
Mdm2C462A/C462A;p53ER/- MEFs exhibited high p21 
expression when compared to either Mdm2-/-
;p53ER/- or Mdm2-/-;MdmX-/-;p53ER/- MEFs, and the 
deletion of MdmX did not significantly impact this 
difference in p21 expression (Figure 4B). 
Unsurprisingly, p53ER levels were also 
significantly increased in Mdm2C462A/C462A;p53ER/- 
and Mdm2-/-;p53ER/- MEFs compared with 
Mdm2+/+;p53ER/- MEFs (Figure 4A), which is 
consistent with the role of the MDM2 RING 
domain in p53 degradation (25). Similarly, 
MDMX was induced by the MDM2 deletion or the 
RING domain mutation due to the loss of E3 
ligase function, which is also explained by the 
previous studies (31-33). We also noticed that 
following 4-OHT treatment p53ER levels continued 
to increase in cells Mdm2C462A/C462A;p53ER/- and 
Mdm2-/-;p53ER/- MEFs (Figure 4A). This effect is 
likely due to the regulation of p53 by other 
ubiquitinating and deubiquitinating enzymes, such 
as HAUSP (34).  
Previous studies have shown that p53 
activation requires its own acetylation (35). The 
acetylation of p53 through interaction with 
cofactors p300/CBP is required for p53 to bind to 
DNA and promote the transcription of p21 and 
other downstream targets (36, 37). Consequently, 
we sought to ascertain whether the MDM2C462A 
mutation affects p53 acetylation, thereby elevating 
p53 transcriptional activity. In order to normalize 
for the variations in p53ER protein levels in each of 
the different MEFs, we calculated the ratio of 
acetylated p53ER to total p53ER protein levels 
(Figure 4C). Though p53ER protein levels were 
consistently highest in cells lacking MDM2 
(Figure 4A), relative p53ER acetylation levels were 
highest in cells harboring the MDM2C462A 
mutation (Figure 4C). 
To confirm these results in vivo, we 
injected tamoxifen into Mdm2+/+;p53ER/-, Mdm2-/-
;p53ER/-, Mdm2C462A/C462A;p53ER/-, 
Mdm2C462A/C462A;MdmX-/-;p53ER/- and Mdm2-/-
;MdmX-/-;p53ER/- mice once daily for three days 
and then analyzed the protein levels of total and 
acetylated p53ER, as well as p53 target gene 
protein levels in spleen, small intestine, colon and 
lung tissues (Figure 5A-D). In all tissues, MDMX 
protein was accumulated in Mdm2-/-;p53ER/- and 
Mdm2C462A/C462A;p53ER/- mouse tissues, however it 
barely controlled p53 transcriptional activity in the 
absence of MDM2 or MDM2 RING domain 
function. On the other hand, p21 and MDM2 
protein levels were highest in 
Mdm2C462A/C462A;p53ER/- and 
Mdm2C462A/C462A;MdmX-/-;p53ER/- mouse tissues. 
We further quantified p21 levels in three 
independent experiments and found that p21 was 
significantly elevated in all Mdm2C462A/C462A;p53ER/- 
and Mdm2C462A/C462A;MdmX-/-;p53ER/- mouse tissues 
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compared to their respective Mdm2-/-;p53ER/- and 
Mdm2-/-;MdmX-/-;p53ER/- counterparts (Figure 5E). 
Further, differences in p53ER acetylation were far 
more apparent in mice than in MEFs, and relative 
p53ER acetylation levels were significantly 
increased in Mdm2C462A/C462A;p53ER/- and 
Mdm2C462A/C462A;MdmX-/-;p53ER/- mouse tissues 
compared to either Mdm2-/-;p53ER/- or Mdm2-/-
;MdmX-/-;p53ER/- tissues (Figure 5F). These 
increases in relative acetylation correlate with both 
the increased p53 activity and early lethality 
observed in mice bearing the MDM2C462A mutation 
and suggest that MDM2 RING function may be 
required for MDM2-mediated p53 transcriptional 
regulation in vivo. 
 
DISCUSSION 
The results of this study have provided some 
clarification of the role of the MDM2 RING 
domain in the regulation of p53 post-
embryogenesis. First, while the two key functions 
of this domain (E3 ligase activity and MDMX 
binding) can be individually lost with little 
consequence in adult, unstressed mice (15, 17), at 
least one of these functions is required to maintain 
tissue homeostasis (Figure 2). When both E3 
ligase activity and MDMX binding capabilities are 
lost, MDM2-p53 binding is not sufficient to 
control basal p53 transcriptional activity and 
prevent p53-induced apoptosis and organismal 
lethality (Figure 1). This is principally 
demonstrated by the early lethality of 
Mdm2C462A/C462A;p53ER/- mice compared to 
Mdm2+/+;p53ER/- mice (Figure 1A).  
Second, the presence of the MDM2C462A 
mutation correlated with both increased p53 
transcriptional activation and acetylation 
compared to the complete absence of MDM2 
(Figure 5). There are several possibilities that 
could explain this observation. First, studies in our 
lab have revealed that the MDM2C462A mutation 
facilitates greater interaction of p53 with histone 
acetyl transferase CBP/p300 (15, 38), an important 
co-activator of p53 that potentiates p53 acetylation 
and transcriptional activity (37). Previous in vitro 
studies have also shown that disruption of the 
MDM2 RING domain disrupts MDM2-MDMX 
binding, but not MDM2 homodimer formation 
(39). Although the MDM2C462A mutation clearly 
disrupts MDM2-MDMX binding, whether or not it 
affects MDM2 homodimerization in vivo remains 
unknown. It is possible that MDM2-MDMX 
binding serves to inhibit MDM2 p300-mediated 
acetylation of p53, but that monomeric or 
homodimeric MDM2 could enhance p300-p53 
interaction and functional activation. As we have 
recently shown that the MDM2 RING domain 
is required for MDM2-MDMX 
heterodimerization but not for MDM2-MDM2 
homodimerization (39), it is possible that the 
MDM2C462A mutant forms homodimer, which 
may have a stronger binding affinity to 
actyltransferase. This would suggest that 
MDM2-mediated inhibition of p53 acetylation by 
p300 requires MDM2-MDMX interaction, which 
is supported by the correlation of the MDM2C462A 
mutation with increased p53 acetylation in mouse 
tissues (Figure 5F). Although overexpressed 
MDMX has been shown to inhibit p300-mediated 
p53 acetylation (40), our data could suggest that 
MDMX alone cannot inhibit p300-p53 interaction 
in vivo, as the loss of MDMX does not appear to 
increase p53 acetylation or activity beyond that 
which is observed in the presence of the 
MDM2C462A mutation (Figure 5), though this 
hypothesis remains to be tested in vivo.  
It is also possible that the MDM2 RING 
domain is required for the inhibitory functions of 
MDM2-p53 binding. For example, in vitro assays 
using an overexpressed human equivalent 
HDM2C464A mutation have demonstrated that a 
functional RING domain is necessary for MDM2-
mediated p53 export (41). In this context, 
MDM2C462A could tether p53 to the nucleus, 
allowing for increased interaction with DNA and 
greater transcriptional activity. The combination of 
increased p53 acetylation and activity with nuclear 
sequestration could explain why mice bearing the 
MDM2C462A mutation demonstrate increased p53 
activity than mice lacking MDM2 (Figure 3). 
This study suggests the following about in vivo 
MDM2-mediated p53 regulation: (1) The MDM2 
RING domain contributes to the regulation of p53 
transcriptional activity in adult mice (2) MDM2-
p53 binding is not sufficient for p53 regulation and 
adult organismal survival (3) In the absence of 
MDM2 or MDM2 RING domain function, 
MDMX does not appear to play a role in 
regulating p53 transcriptional activity in adult 
mice. However, it remains possible that the 
observations made in this study could be specific 
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to the MDM2C462A mutation or p53ER. In future 
studies it would be useful to confirm these results 
using another model system, such as mice lacking 
the MDM2 RING domain, containing an alternate 
RING-disrupting mutation, or an alternate 
inducible p53 model. The results of this study also 
have implications for p53-inducing therapies. 
Small molecule compounds that inhibit MDM2-
p53 interaction, like nutlin-3a, have been widely 
used to facilitate p53 activation (42). Our study 
suggests the possibility that compounds targeting 
MDM2 RING domain function could produce 
even more robust p53 activation. 
 
EXPERIMENTAL PROCEDURES 
Genetically engineered mice and in vivo studies— 
To generate mice bearing the genotypes used in 
this study, we bred p53ER/- mice with mice from 
several different backgrounds, including Mdm2-/-, 
Mdm2C462A/C462A, and MdmX-/- (10, 14, 20). All 
experimental procedures were approved by the 
University of North Carolina Institutional Animal 
Care and Use Committee. To restore p53ER 
function, mice were intraperitoneally injected with 
1mg/kg tamoxifen (Sigma, T5648) according to 
body weight. 	
Cell culture—MEF cells were isolated from 
E13.5-E16.5 embryos and cultured in a 37oC 
incubator with 5% CO2 in DMEM supplemented 
with 10% fetal bovine serum (Gibco) and 100 
IU/ml penicillin (Gibco). To restore p53ER 
function in vitro, cultured MEFs were exposed to 
100 nM 4-OHT (Sigma, H7904) for the indicated 
amounts of time. 
 
Immunoblot analysis—Protein was extracted from 
organs and cells as described previously (14). 
Protein lysates were fractionated on SDS 
polyacrylamide gels and transferred onto 
nitrocellulose membranes. Procedures and 
conditions for immunoblotting were described 
previously. The following antibodies were 
purchased commercially: monoclonal mouse anti 
MDMX (MDMX-82, Sigma), monoclonal mouse 
anti actin (MAB1501, EMD Millipore), polyclonal 
rabbit anti acetyl-p53 (K379, Cell Signaling 
Technology Inc) and polyclonal goat anti p21 (C-
19, Santa Cruz Biotechnology). The monoclonal 
mouse anti p53 (pAB122) and monoclonal mouse 
anti MDM2 (2A10) were homemade by our 
laboratory. The intensity of the bands in the linear 
range of exposure was quantified using ImageJ 
1.46r. 	
qRT-PCR analysis of mRNA—Total RNA was 
prepared from mouse tissues using Trizol® 
Reagent (Invitrogen, #15596-026). RNA 
concentration was determined with a NanoDrop 
spectrophotometer (Thermo Scientific, 
NanoDrop™ 2000c) and quality was assessed by 
agarose gel electrophoresis. cDNA was 
synthesized using Superscript III reverse 
transcriptase (Invitrogen, 18080-051). qRT-PCR 
was performed with SYBR Green probes using the 
Applied Biosystems 7900HT Fast Real-Time PCR 
system. Thermal cycling conditions were 50°C for 
2 min, 95°C for 10 min, followed by 40 cycles of 
95°C for 15 sec and 60°C for 1 min. Target gene 
transcript levels were normalized to beta-actin 
transcript levels obtained in each sample via the 
subtraction of the Ct value of beta-actin from the 
Ct value for each target gene. Results were 
expressed as the fold-change in transcript levels. 
Primers used for qRT-PCR were as follows: 
p21: 5’TCCACAGCGATATCCAGACA3’ and 
5’AGACAACGGCACACTTTGCT3’. 





β-Actin: 5’GGCTGTATTCCCCTCCATCG3’ and 
5’CCAGTTGGTAACAATGCCATGT-3’. 
 
Hematoxylin and eosin staining and TUNEL assay 
—Tissues were dissected, flushed gently with cold 
PBS, fixed in 10% formalin overnight, dehydrated 
in 50% ethanol, and stored in 70% ethanol until 
they were transferred to the Histology Research 
Core Facility at UNC for paraffin embedding. The 
tissues were then cut into 4 µm sections and then 
processed for Hematoxylin and eosin staining 
(H&E). TUNEL staining for apoptosis was 
performed using the Apoptag Peroxidase In Situ 
Apoptosis Detection Kit according to 
manufacturer’s instructions. TUNEL stained tissue 
was analyzed using an Olympus IX-81 microscope 
fitted with a SPOT camera and software.  	
Statistical analysis—Results are represented as 
mean ± standard error of the mean. Quantitative 
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PCR data and immunoblotting quantifications 
were evaluated for significance using the unpaired 
t test. A p value <0.05 was considered significant 
for all analyses. Significant differences between 
experimental groups were: *P < 0.05 or **P < 0.01. 
Calculations were performed using GraphPad 
Prism 5 software. 	
Ethics statement—This investigation has been 
conducted in accordance with ethical standards, 
the Declaration of Helsinki, national and 
international guidelines, and has been approved by 
the authors' institutional review board. 
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Figure 1. Mice bearing Mdm2C462A exhibit early lethality following p53ER activation by 4-OHT. 
(A) Kaplan-Meier curve depicting the survival of Mdm2+/+;p53ER/- (n=5) and Mdm2C462A/C462A;p53ER/- (n=5) 
mice treated with daily injection of tamoxifen. (B) Kaplan-Meier curve depicting the survival of Mdm2-/-
;p53ER/- (n=5) and Mdm2C462A/C462A;p53ER/- (n=5) mice treated with daily injection of tamoxifen. (C) 
Kaplan-Meier curve depicting the survival of Mdm2-/-;MdmX-/-;p53ER/- (n=5) and Mdm2C462A/C462A;MdmX-/-
;p53ER/- (n=5) mice treated with daily injection of tamoxifen. (D) Kaplan-Meier curve depicting the 
survival of Mdm2C462A/C462A;p53ER/- (n=5) and Mdm2C462A/C462A;MdmX-/-;p53ER/- (n=5) mice treated with 
daily injection of tamoxifen. (E) Kaplan-Meier curve depicting the survival of Mdm2-/-;p53ER/- (n=5) and 
Mdm2-/-;MdmX-/-;p53ER/- (n=5) mice treated with daily injection of tamoxifen. 
 
Figure 2. Mdm2 RING mutation Mdm2C462A/C462A exacerbated p53-induced mouse intestine atrophy 
and cell apoptosis.  
 (A-B) Mice of the indicated genotypes in a p53ER/- background were treated with daily tamoxifen 
injection for 3 days and harvested. Hematoxylin and eosin (H&E) staining was used to detect the tissue 
structure of colon (A) and small intestine (B) from the different genotypes. Scale bar 50µm. (C-D) 
Peroxidase TUNEL staining was perform as a cellular marker of apoptosis in colon (C) and small 
intestine (D) from the above mice. The TUNEL stain is brown and hematoxylin nuclear counterstain is 
blue. Scale bar 50µm.  
 
Figure 3. Functional Mdm2 RING inactivation correlates with enhanced p53 target gene 
transcription in vivo. 
 (A) MEFs of the indicated genotypes in a p53ER/- background were treated with 4-OHT for the indicated 
times and harvested. Then, qRT-PCR was used to measure the mRNA levels of p21, puma, and bax 
relative to those present in untreated Mdm2+/+;p53ER/- MEFs. (B-C) Mice of each indicated genotypes 
(n=3) in a p53ER/- background were treated with daily tamoxifen injection for 3 days and harvested. Then, 
qRT-PCR was used to measure the mRNA levels of p21, puma, and bax present in small intestine (B) and 
lung (C) relative to those present in tissues from Mdm2+/+;p53ER/- mice. Data are means ± SD calculated 
from three independent experiments and normalized to Actin. *p<0.05, **p<0.01. 
 
Figure 4. Mdm2 RING mutation potentiates p53 acetylation and downstream target protein 
expression in MEF cells. 
 (A) MEFs of the indicated genotypes in a p53ER/- background were treated with 4-OHT for the indicated 
times and harvested for Western blot analysis with the indicated antibodies. (B) The levels of p21 from 
three independent experiments as in (A) were quantified using densitometry and normalized to untreated 
Mdm2+/+;p53ER/- MEFs. (C) The ratio of acetyl-p53ER to total p53ER protein from three independent 
experiments as in (A) were quantified using densitometry and normalized to untreated Mdm2+/+;p53ER/- 
MEFs. Data are represented as means ± SD calculated and were normalized to Actin. *p<0.05, **p<0.01. 
 
Figure 5. Mdm2 RING mutation potentiates p53 acetylation and downstream target protein 
expression in vivo. 
 (A-D) Mice of the indicated genotypes in a p53ER/- background were treated with daily tamoxifen 
injection for 3 days. Spleen (A), small intestine (B), colon (C), and lung (D) tissues were harvested for 
Western blot analysis with the indicated antibodies. (E) The levels of p21 from three independent 
experiments as in (A-D) were quantified using densitometry and normalized to Mdm2+/+;p53ER/- mouse 
tissues. (F) The acetyl-p53ER protein level from three independent experiments as in (A-D) were 
quantified using densitometry and normalized to Mdm2+/+;p53ER/- mouse tissues. Data are means ± SD 
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